The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
September 1st 2025
Research reveals that increased sedentary time significantly impacts neurodegeneration and cognitive decline in older adults, especially those genetically at risk for Alzheimer’s.
Alzheimer Biomarkers pTau217 and pTau181 Show High Group-Level Correlation With Trial End Points
April 2nd 2025Investigators at AD/PD 2025 presented new data showing that changes in plasma p-tau217 and p-tau181 closely correlate with clinical outcomes in anti-amyloid therapy trials for Alzheimer disease.
NeuroVoices: Cynthia Lemere, PhD, on Exploring the Role of Complement in ARIA and CAA
April 2nd 2025The professor of neurology at Brigham and Women’s Hospital gave clinical insights on the therapeutic potential of targeting compliment as a way to mitigate risk for amyloid-related imaging abnormalities from antiamyloid therapies.
Higher CSF Aß42/Total Tau Ratio Associated With Increased ARIA Risk in Lecanemab
April 1st 2025Research suggests that CSF ATI ratios could serve as a biomarker for identifying patients with Alzheimer disease at higher risk of ARIA during lecanemab treatment, aiding in safer patient management.
Eli Lilly Announces Expanded Services to Early Diagnosis and Access Alzheimer Disease Care
March 31st 2025Eli Lilly’s expanded LillyDirect platform tackles barriers in Alzheimer disease diagnosis and care, offering telehealth and in-person options through Healthgrades and Synapticure, with a focus on timely access and patient support.
Neflamapimod Shows Promising Phase 2b Extension Data in Dementia With Lewy Bodies
Published: March 12th 2025 | Updated: March 13th 2025Participants who received the new batch of capsules during the extension phase experienced a lower incidence of falls compared with those taking the old capsules or placebo.
Low-Dose Interleukin-2 Reduces Proinflammatory Biomarkers in Phase 2 Study of Alzheimer Disease
February 10th 2025Monthly cycles of low-dose IL-2, or COYA 301, resulted in statistically significant decreases in proinflammatory biomarkers and increases in anti-inflammatory cytokine IL-4 vs placebo.